Today, we will be at the annual Stanford Drug Discovery Symposium. Yesterday, our CEO Charlene Liao had the pleasure of speaking with Dr. Brian Druker, recipient of the 2023 Stanford Drug Discovery Symposium Lifetime Achievement Award. If you're at #SDDS2023, please say Hello!

#DYK that myeloid checkpoints could be game-changing targets for the field of #cancerimmunotherapy? Join our CEO Charlene Liao's presentation at the Cambridge Healthtech Institute's 2nd Annual “Emerging Targets for Oncology and Beyond” conference at #PEGS23 next week. See you there!

We are presenting clinical data for IO-202 for the first time at #EHA2023 next month! IO-202 is our first-in-class #myeloid #checkpointinhibitor targeting LILRB4 (aka ILT3) for the treatment of #AML and #CMML. Read below for info to attend the presentation ⬇️

Why are we so excited about #immunotherapy? Because we’re playing a big role in its evolution. This week at #PEGS23 our CEO, Charlene Liao discussed our scientific approach and robust pipeline targeting myeloid checkpoints. Learn more at Immune-Onc.com

Next Tue., May 23, our CEO Charlene Liao and CFO Chris Whitmore look forward to meeting with investors 1:1 at the 2023 Wells Fargo Virtual Private Biotech Symposium to discuss how our platform of #myeloid #checkpointinhibitors is reigniting the field of #immunotherapy. #biotech

#DYK that our first-in-class humanized IgG1 monoclonal antibody, IO-202, targets the myeloid inhibitory receptor LILRB4 to reverse immune suppression in the tumor microenvironment? Visit our first clinical data presentation showing this in action at #EHA2023.

#Breaking: Our team and investigators will share the first clinical data on IO-202 (anti-LILRB4), our first-in-class #myeloid #checkpointinhibitor for the treatment of #AML and #CMML at the #EHA2023 congress in Frankfurt. Learn more: immune-onc.com/pr-posts/immun…

Next week at the 3rd Tumor Myeloid-Targeted Therapies Summit in Boston, our very own Dr. Luke Chung will present encouraging Ph 1 data for IO-108, our first-in-class antibody targeting LILRB2 (ILT4). We hope to see you there (Wed., 7/19 - 1:30 PM)! bit.ly/3rhgQka

Excited to share a collaboration with Roche evaluating IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) for the 1st line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma bit.ly/3I42pFk

Great news! The FDA has granted IO-202 Orphan Drug Designation for the treatment of chronic myelomonocytic leukemia (CMML). Our Ph 1 study of IO-202 in combination with azacitidine is also currently enrolling newly diagnosed CMML patients. Read more here: bit.ly/48pyWQT

Exciting News! The San Francisco Business Times recognized our Orphan Drug Designation for IO-202 for #CMML as a recent breakthrough by women-led life sciences companies in the Bay Area. Read more here: bizjournals.com/sanfrancisco/n…

#News: We look forward to presenting interim clinical data from our Phase 1b trial of IO-202 for the treatment of chronic myelomonocytic leukemia (#CMML) at the upcoming #EHA2024 Congress. View the press release for details: bit.ly/4bjpnoQ

New from Immune-Onc Therapeutics at #EHA2024! Today, we will present additional positive interim Ph 1b expansion data for IO-202 in #CMML patients. The study shows early and sustained complete remissions among patients, regardless of their prognosis or mutation status. bit.ly/3Rs1SC7

We're thrilled to announce that Immune-Onc will present new IO-202 data for chronic myelomonocytic leukemia (CMML) at #ASH24! Join us to learn about the potential of our anti-LILRB4 antibody in addressing CMML, an underserved cancer with limited treatments bit.ly/40sNUW4

Our Ph 1 data on IO-108 was published in Journal for ImmunoTherapy of Cancer ! · Durable responses in advanced solid tumors · Promising monotherapy & combo results with pembrolizumab · Potential to overcome resistance to checkpoint inhibitors Read the full press release: bit.ly/4fu6e5N

We’re proud to see Immune-Onc Therapeutics's IO-102 Ph 1 #CMML study featured in The Leukemia & Lymphoma Society's announcement highlighting new data showing progress for hard-to-treat blood cancers. Looking forward to sharing more updates on the study at #ASH2024. bit.ly/3Oqvvly

Immune-Onc Therapeutics will present important updates on its Phase 1b data on IO-202 for CMML. Don’t miss the oral presentation at #ASH2024 on Monday!

Today, we are proud to present groundbreaking new Phase 1b data on IO-202 for #CMML at #ASH2024! ✔️ CR: 50% | ORR: 66.7% ✔️ High LILRB4 expression: CR: 83%; ORR: 100% ✔️ 40% bridged to transplant ✔️ Additional clinical benefits Learn more: bit.ly/3OIEI8V

We’re back from #ASH2024 and inspired by the energy and engagement around our oral presentation on IO-202 for #CMML. This is a key step toward new hope for people with this rare blood cancer. Thank you to everyone who joined us. ICYMI: bit.ly/3OIEI8V

The first patient has been dosed in our global Ph 1b/2 trial evaluating IO-108 for 1st-line treatment of HCC in clinical collaboration with Roche! A major step forward in our mission to advance cancer care. Learn more: bit.ly/4ihX9Op